Randomized trial shows performance declines with longer winning streaks in college basketball, suggesting strategic implications for teams.
The hot hand literature asks whether success predicts success. This paper asks the inverse question: conditional on a team continuing to win, does the quality of its performance decay as the streak lengthens? Using 69,022 Division I versus Division I team-game rows across seven college basketball seasons, with point-in-time KenPom opponent adjustment and no future leakage, we estimate the effect of entering win-streak depth on opponent-adjusted margin residual within team-season fixed effects, with standard errors clustered on 2,306 team-seasons. The raw within-team estimate is -0.3207 points per game of depth (SE 0.0280, t = -11.5); an own-construction memoryless null, built at each team’s own rate and passed through the identical pipeline, reproduces a mechanical floor of -0.2238; the claim of this paper is the excess beyond that floor, -0.0969 per game of depth (0 of 200 null replicates as negative; lower-tail p at or below .005). The raw estimate carries a pre-registered threshold shape: flat through depths 1-2, onset near depths 3-5, deepening to roughly -3 points at depths 13 and beyond. The naive cross-team specification is opposite-signed, a rating-lag artifact the within-team design removes. The effect survives fatigue, recent-form, and opponent-preparation controls. A loss-streak placebo is opposite-signed but largely mechanical under its own null. In the decisive horse race, accumulated overperformance collapses to insignificance while duration survives. A pre-registered, hash-locked one-shot replication on the held-out 2021-22 season passes both frozen criteria (coefficient -0.4169, t = -4.6). A validated tennis instrument returns a concordant phase-tier residual in two universes, and an EPL construction replicates enter-depth compression locally. The duration-burden interpretation is [supported]; the causal mechanism is [open]; two pre-registered composition tests remain open and gate the strongest public version of the claim.
No takes yet. Share an insight, caveat, or question.
James Castranova (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: